- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03896971
Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia
Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia
To the investigator's Knowledge this is the first study that will assess Treatment with thrombopoietin Mimetic plus immunosuppressiveTherapy in Egyptian Patients with Aplastic Anaemia.
Aim of the work :
- To evaluate the efficacy, tolerability and toxicity of the combination of thrombopoietin mimetic and immunosuppressive therapy in Egyptian patients with AA.
- To study the influence of this combination on patients' quality of life.
- To access evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome , acute leukemia or development of fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aplastic anemia (AA) is a bone marrow failure syndrome that, although benign in nature, it influences patients' quality of life and carries poor prognosis.The pathophysiological basis of development of acquired AA include immune-mediated attack, inherent hematopoietic stem cell insufficiency and telomere defects. Bone marrow transplantation (BMT) is the only curative treatment for AA. Unfortunately it is unavailable for many patients due to lack of matched donors furthermore others are ineligible for BMT due to old age or co-morbid conditions. Immunosuppressive therapy was the mainstay of treatment for AA for many years, however many patients developed resistance or refractoriness. Immunosuppressive therapy was in the form of antithymocyte globulin (ATG) which gave hematologic response in nearly 50% of patients , adding cyclosporin A increases this response to 70%. Why some patients became resistant to immunosuppressive therapy ? The answer is not known.
Thrombopoietin mimetic (Eltrombopag) was firstly FDA approved for treatment of immune thrombocytopenic purpura. Numerous clinical trials proved the efficacy of anthropometric mimetic in patients with refractory severe AA, leading to its FDA approval for this group of patients. Some researchers proven the efficacy of thrombopoietin mimetic in patients with moderate aplastic anemia.
This study aimed to asses the combination of thrombopoietin mimetic and immunosuppressive therapy in patients with AA.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt, 71515
- Assiut university hospital Internal Medicine Department Hematology and BMT Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible for treatment with thrombopoietin mimetic.
- Willing to participate in the study and signed informed consent.
- Unavailability of BMT -
Exclusion Criteria:
- Patient with inherited aplastic anemia
- Underlying immune deficiency
- Contra indication to cyclosporin A
- Endstage hepatic or renal disease
- Pregnancy and lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Thrombopoietin mimetic plus immunosuppressive therapy
The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months.
Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
|
This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital.
Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
Other Names:
|
No Intervention: Immunosuppressive therapy
A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with hematologjc response
Time Frame: 2-3months
|
d) Bone marrow cellularity (time frame (2-3 months): increase bone marrow cellularity from baseline |
2-3months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with one of the following
Time Frame: 2-3months
|
|
2-3months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Safinaz Hussien, MD, Assiut University
- Principal Investigator: Sawsan A Abdelaal, M.B.B.Ch, Assiut University
Publications and helpful links
General Publications
- Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010 Sep 22;304(12):1358-64. doi: 10.1001/jama.2010.1376. Erratum In: JAMA. 2010 Nov 3;304(17):1901.
- Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991 May 9;324(19):1297-304. doi: 10.1056/NEJM199105093241901.
- Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003 Feb 15;101(4):1236-42. doi: 10.1182/blood-2002-04-1134. Epub 2002 Oct 10.
- Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003 Mar 5;289(9):1130-5. doi: 10.1001/jama.289.9.1130.
- Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009;60:193-206. doi: 10.1146/annurev.med.60.042307.181154.
- Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. doi: 10.1182/blood-2013-10-534743. Epub 2013 Dec 17.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Bone Marrow Diseases
- Hematologic Diseases
- Bone Marrow Failure Disorders
- Anemia
- Anemia, Aplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- SKhaled19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aplastic Anemia
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
University of UtahNovartisCompletedSevere Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic AnemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Severe Aplastic Anemia | Refractory Severe Aplastic AnemiaUnited States
-
Peking University People's HospitalRecruiting
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingSevere Aplastic AnemiaUnited States
-
Federal Research Institute of Pediatric Hematology...RecruitingAcquired Aplastic AnemiaRussian Federation
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaboratorsCompleted
-
Nagoya UniversityUnknownAcquired Aplastic Anemia.Japan
-
Navy General Hospital, BeijingPeking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsUnknownSevere Aplastic AnemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
Clinical Trials on Combination of thrombopoietin mimetic and cyclosporin A
-
Shandong UniversityNational Natural Science Foundation of ChinaUnknown
-
Institute of Hematology & Blood Diseases HospitalUnknownUrination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,China
-
Institute of Hematology & Blood Diseases HospitalUnknownUrination Disorders | Thrombosis | Proteinuria | Anemia, Hemolytic | Hemoglobinuria, Paroxysmal | Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Bone Marrow Failure | Aplastic Anemia,China
-
Hospital Son EspasesLinde AGCompletedPulmonary Disease, Chronic ObstructiveSpain
-
Ming HouPeking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsCompletedPurpura | Idiopathic Thrombocytopenic PurpuraChina
-
Hospices Civils de LyonCompletedInfection, Bacterial | Infection ViralFrance
-
Stanford UniversityNot yet recruitingHeart FailureUnited States
-
Hospices Civils de LyonCompletedST Elevation Acute Myocardial InfarctionFrance, Spain, Belgium
-
Shanghai Junshi Bioscience Co., Ltd.WithdrawnPrimary Condition: Advanced TumorsChina
-
Nanjing NingQi Medicine Science and Technology...The First Affiliated Hospital with Nanjing Medical University; Fudan University and other collaboratorsUnknownColorectal Cancer | Chemotherapy-induced Peripheral Neuropathy